'USP Chapter 797: Understanding the Revisions' Technical Paper By Baxa Corporation's Mike Hurst Now Accessible on Expert411.com For Media and Professional Reference
 |
| Baxa Corporation |
|
|
|
|
The "USP Chapter 797: Understanding the Revisions" technical paper, authored by Baxa Corporation's Mike Hurst, RPh, MBA, is now accessible at Expert411.com for media and professional reference. USP Chapter 797 became official on January 1, 2004 The first major revision was released on December 3, 2007, following years of soliciting feedback and the review of hundreds of responses by the USP Sterile Compounding Committee. June 1, 2008, is the effective date for the new standards. This paper summarizes the most important changes to USP 797. Englewood, CO (PRWEB) March 31, 2008 -- The "USP Chapter 797: Understanding the Revisions" technical paper, authored by Baxa Corporation's Mike Hurst RPh, MBA, is now accessible at Expert411.com for media and professional reference. USP Chapter 797 became official on January 1, 2004. The first major revision was released on December 3, 2007, following years of soliciting feedback and the review of hundreds of responses by the USP Sterile Compounding Committee. June 1, 2008, is the effective date for the new standards. This paper summarizes the most important changes to USP 797. This technical paper and links to ten other related publications are now available along with Hurst's Expert Profile information at http://expert411.com/_wsn/page3.html. Other topics include: - Overview of USP 797: Pharmaceutical Compounding -- Sterile Preparations
- Oral Medication Dispensers in Clinical Research
- Enteral Feeding Misconnections
- Environmental Controls for Sterile Compounding
- The Limitations of Isolators
- Pharmacy Considerations for Syringe Batch Processing
- Safe Handling of Hazardous Drugs
- USP 797 Requirements for Automated Compounders
- Technical Bulletin for Risk Level Assessment
- Outsourcing for USP 797
Hurst worked for 18 years at Swedish Medical Center in Seattle, Washington, in operational management, including positions as IV Supervisor and Assistant Director of Pharmacy. His implementation of a syringe infusion system in 1984 had national implications. For the next nine years Hurst wrote, spoke, consulted and acted as a reference site for syringe infusion installations across the country.Moving to industry full time in 1994, Hurst joined Baxa Corporation as Vice President of Infusion Systems. His job duties have included customer support for syringe infusion system installations, new business and product development roles, and professional services support for various Baxa pharmacy and nursing product lines. Hurst also consulted with a hospital system in the development of a comprehensive USP 797 compliance template that can be applied in other hospital pharmacies. About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications. Key products include the PadLock® Set Saver, Rapid-Fill™ Automated Syringe Fillers, Exacta-Med® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, and Exacta-Mix™ and MicroMacro™ Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Finland, France, Germany, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide. Further information is available at http://www.baxa.com Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
http://www.baxa.com Maggie Chamberlin Holben, APR, Absolutely Public Relations
303.984.9801, 303.669.3558
http://www.absolutelypr.com # # #
Simillar Articles
|
